Risk of malaria in the region of destination |
Recommended prophylaxis |
Remarks |
Very low risk of Plasmodium spp infection |
Mosquito bite precautions only |
Very few regions in Central and East Asia and in North Africa |
Risk of P vivax malaria only |
Mosquito bite precautions + chemoprophylaxis (chloroquine or atovaquone/proguanil, doxycycline, or mefloquine)a |
Some Caribbean islands, some regions in Central and South America and Central Asia |
Risk of P falciparum malaria, plasmodium resistance to chloroquine |
Mosquito bite precautions + chemoprophylaxis (atovaquone/proguanil, doxycycline, or mefloquine)a |
The majority of malaria-endemic regions worldwide |
Risk of P falciparum malaria + documented mefloquine resistance |
Mosquito bite precautions + chemoprophylaxis (atovaquone/proguanil or doxycycline)a |
Southeast Asia: some regions of Myanmar, Thailand, and Cambodia |
a In regions with very low risk of P falciparum infection and documented multidrug resistance, the use of mosquito bite precautions only and SBET is permitted. | ||
Adapted from WHO International Travel and Health 2012 (updated 2017). | ||
SBET, standby emergency treatment; WHO, World Health Organization. |